Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-rg895 Total loading time: 0 Render date: 2025-05-01T04:04:06.216Z Has data issue: false hasContentIssue false

Chapter 18 - The Use of Estrogens and Progestogens in Menopausal Hormone Therapy

Published online by Cambridge University Press:  18 June 2020

By
Kugajeevan Vigneswaran  and
Haitham Hamoda
Edited by
Nicholas Panay ,
Paula Briggs  and
Gabor T. Kovacs
Nicholas Panay
Affiliation:
Queen Charlotte's & Chelsea Hospital, London
Paula Briggs
Affiliation:
Liverpool Women's NHS Foundation Trust
Gabor T. Kovacs
Affiliation:
Monash University, Victoria
Get access

Summary

In November 1929, clinicians first attempted to develop an ‘ovary stimulating hormone’ extracted from the human placenta for the treatment of symptoms resulting from the menopause. The team at Montreal General Hospital named it ‘Emmenin’ and it had to be purified from the urine of pregnant women to be administered orally. It was later discovered that pregnant mares’ urine could provide an abundant supply of a compound with high estrogenic activity. This conjugated equine estrogen (CEE) was commercially produced as Premarin and made available as an oral estrogenic agent in 1939.

Type
Chapter
Information
Managing the Menopause , pp. 177 - 186
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline [NG23]. November 2015.Google Scholar
International Menopause Society. IMS recommendations on women’s midlife health and menopause hormone therapy. 2016.Google Scholar
Hamoda, H, Panay, N, Arya, R, et al. British Menopause Society. The British Menopause Society and Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2016;22(4):165–83.Google Scholar
Hamoda, H. British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency.Google Scholar
North American Menopause Society. The 2017 hormone therapy position statement of he North American Menopause Society.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×